N034519 N0 Ruling Active

The tariff classification of Pemetrexed Disodium (CAS-150399-23-8) and Rizatriptan Benzoate (CAS-145202-66-0) in bulk form, from China and Taiwan, respectively

Issued August 8, 2008 by U.S. Customs and Border Protection.

Tariff classification

HTS codes: 2933.99.5590, 2933.59.5300

Headings: 2933

Product description

The first product, Pemetrexed Disodium, is a type of enzyme inhibitor and is used in the treatment of pleural mesothelioma and advanced non-small cell lung cancer. The second product, Rizatriptan Benzoate, is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist and is indicated for the acute treatment of migraine attacks with or without aura in adults.

CBP rationale

The applicable subheading for the Pemetrexed Disodium in bulk form will be 2933.59.5300 Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other. The applicable subheading for the Rizatriptan Benzoate in bulk form will be 2933.99.5590 Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Other: Other: Aromatic or modified aromatic: Other: Drugs: Drugs primarily affecting the central nervous system: Analgesics, antipyretics and nonhormonal anti-inflammatory agents: Other.

Full text

N034519 August 8, 2008 CLA-2-29:OT:RR:NC:N2:238 CATEGORY: Classification TARIFF NO.: 2933.59.5300; 2933.99.5590 Ms. Inge Forstenzer Ren-Pharm International Ltd. 350 Jericho Turnpike, Suite 204 Jericho, NY 11753 RE: The tariff classification of Pemetrexed Disodium (CAS-150399-23-8) and Rizatriptan Benzoate (CAS-145202-66-0) in bulk form, from China and Taiwan, respectively Dear Ms. Forstenzer: In your letter dated July 14, 2008, you requested a tariff classification ruling. The first product, Pemetrexed Disodium, is a type of enzyme inhibitor and is used in the treatment of pleural mesothelioma and advanced non-small cell lung cancer. The second product, Rizatriptan Benzoate, is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist and is indicated for the acute treatment of migraine attacks with or without aura in adults. The applicable subheading for the Pemetrexed Disodium in bulk form will be 2933.59.5300 Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure: Other: Drugs: Aromatic or modified aromatic: Other.” Pursuant to GN13 HTSUS, the rate of duty will be free. The applicable subheading for the Rizatriptan Benzoate in bulk form will be 2933.99.5590 Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Other: Other: Aromatic or modified aromatic: Other: Drugs: Drugs primarily affecting the central nervous system: Analgesics, antipyretics and nonhormonal anti-inflammatory agents: Other.” Pursuant to GN13 HTSUS, the rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at 646-733-3033. Sincerely, Robert B. Swierupski Director, National Commodity Specialist Division

View original on CBP CROSS →

More rulings on the same tariff codes

N334168 August 15, 2023

The tariff classification of Ensifentrine (CAS No. 1884461-72-6) in bulk powder form, from Portugal

N329297 December 7, 2022

The tariff classification of Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk powder form, from Taiwan

N329037 November 21, 2022

The tariff classification of Trilaciclib Dihydrochloride (CAS No. 1977495-97-8) and Ruxolitinib Phosphate (CAS No. 1092939-17-7) in bulk form, from Taiwan

N320984 September 7, 2021

The tariff classification of Vibegron (CAS No. 1190389-15-1) in bulk form, from India

N318947 May 14, 2021

The tariff classification of Vericiguat (CAS No. 1350653-20-1) in bulk form and Verquvo® Tablets in dosage form, from Germany

N317830 March 22, 2021

The tariff classification of Sitagliptin Phosphate Monohydrate (CAS No. 654671-77-9) in bulk form, from Spain

N316508 January 13, 2021

The tariff classification of Indomethacin (CAS No. 53-86-1) in bulk powder form, from Brazil

N303158 March 15, 2019

The tariff classification of Bicalutamide (CAS No. 90357-06-5), Linagliptin (CAS No. 668270-12-0) and Aripiprazole (CAS No. 129722-12-9) in bulk powder form, from India

N303161 March 15, 2019

The tariff classification of Imatinib (CAS No. 152459-95-5) and Tofacitinib Citrate (CAS No. 540737-29-9) in bulk powder form, from Italy

N302078 December 20, 2018

The tariff classification of VITRAKVI™ capsules in dosage form and Larotrectinib (CAS No. 1223403-58-4) in bulk form, from the United States and imported from the United Kingdom

Searching CBP rulings the smart way

TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.

Book a demo →